Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 31 people who received a medicine called adalimumab. The trial was looking at how the medicine affected a condition involving inflammation inside the eye. Researchers tracked participants over time — 30 people reached the 10-week point, and 12 reached the 50-week point. The study was measuring a combined set of goals, where a participant was considered to have met the target if they improved in at least one of four areas (such as better vision, reduced need for other medicines, better control of eye inflammation, or reduced fluid and inflammation visible on eye scans) without getting noticeably worse in any of the others. The reported data shows that, out of the 31 people who started the trial, 21 participants met at least one of those improvement goals at some point during the study. The reported data also shows that 12 participants met those goals at the 50-week stage. No comparison group (such as a placebo or dummy treatment group) was included in the data submitted, so these numbers reflect only the group who received adalimumab. Some figures — such as the exact breakdown of which specific improvement goals were met — were not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have an autoimmune eye condition called uveitis that is serious enough to threaten your vision.
- Your uveitis has not responded to prednisone (a steroid) and at least one other medication that suppresses the immune system (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or you were unable to take these medications because of side effects.
Who may not be able to join:
- You have another serious health condition that could affect your ability to take part in the trial (confirm with trial site).
- You have previously used or are currently using a medication called cyclophosphamide.
- You are unwilling or unable to receive multiple injections as part of the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cumulative Endpoint; Cumulative Endpoint
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.